CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022
November 23, 2022 at 04:02 pm EST
Share
On November 21, 2022, Ralph Snyderman, M.D., notified the Board of Directors of CareDx Inc. that he will be resigning from the Board and all committees of the Board, effective as of December 31, 2022. Dr. Snyderman's decision to resign was not due to any disagreements with the Company on any matter relating to the Company's operations, policies or practices.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
